|
Synonyms: Andexxa® | coagulation factor Xa (recombinant), inactivated-zhzo | Ondexxya® | PRT064445 | PRT4445 | r-antidote
andexanet alfa is an approved drug (FDA (2018), EMA (2019))
Compound class:
Peptide or derivative
Comment: Andexanet alfa is a recombinant modified human Factor Xa (FXa) protein that acts as a mimetic of endogenous human factor Xa, and which was developed as a universal antidote to reverse thhe anticoagulant effects of direct or indirect FXa inhibitors. Information regarding the invention of andexanet alfa is available in patent WO2009042962 [2].
View more information in the IUPHAR Pharmacology Education Project: andexanet alfa |
| References |
|
1. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB et al.. (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 19 (4): 446-51. [PMID:23455714] |
|
2. Lu G, Phillips DR, Andre P, Sinha U. (2009)
Antidotes for factor xa inhibitors and methods of using the same. Patent number: WO2009042962 A2. Assignee: Portola Pharm Inc and Inventors.. Priority date: 28/08/2007. Publication date: 02/04/2009. |
|
3. Rogers KC, Finks SW. (2019)
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Am J Med, 132 (1): 38-41. [PMID:30053385] |
|
4. Shaw JR, Siegal DM. (2018)
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. Res Pract Thromb Haemost, 2 (2): 251-265. [PMID:30046727] |
